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license (http://creativewhich oligomeric neurotoxic species of amyloid-b appears to contribute synaptic pathology.Although
a number of clinical pathologic studies have been performed with limited sample size, there are no
systematic studies encompassing large samples. Therefore, we performed a meta-analysis study.
Methods: We identified 417 publications reporting postmortem synapse and synaptic marker loss
from AD patients. Two meta-analyses were performed using a single database of subselected publi-
cations and calculating the standard mean differences.
Results: Meta-analysis confirmed synaptic loss in selected brain regions is an early event in AD
pathogenesis. The second meta-analysis of 57 synaptic markers revealed that presynaptic makers
were affected more than postsynaptic markers.
Discussion: The present meta-analysis study showed a consistent synaptic loss across brain regions
and that molecular machinery including endosomal pathways, vesicular assembly mechanisms,
glutamate receptors, and axonal transport are often affected.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Endosomal/lysosomal pathway; Meta-analysis; Synapse markers; Synapse number1. Introduction
Synaptic damage has been extensively studied in Alz-
heimer’s disease (AD; reviewed by [1]) because in this
neurodegenerative disorder the loss of synapses is the best
correlate to the cognitive deficits [2,3]. Moreover, amyloid
beta (Ab) oligomers appear to be formed and transported
at the synapses and interfere with glutamate receptors [4,5]
and synaptic functioning by interactions with presynaptic
and postsynaptic receptors such as EphA [6], EphB2 [7],rs report a conflict of interest.
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commons.org/licenses/by-nc-nd/4.0/).PrPc [8], mGluR5 [9], NMDA-R [10], frizzled, insulin-R,
and nerve growth factor receptor among others [11].
The loss of synapses in AD and other neurodegenerative
disorders is most likely part of a spectrum of alterations
and pathogenic molecular cascades which begins with
alterations in the synaptic vesicle machinery and glutamate
receptors, progressing to mitochondrial dysfunction,
reduced axonal flow, and loss of neurotrophic support [12].
Together, these alterations might manifest at early stages
as synaptic dysfunction that could be reversible; however,
as the process advances and alterations become irreversible,
damage to synapses and spines might occur resulting even-
tually in synaptic and neuronal loss.
In the very early stages of AD, clinicallymanifested as am-
nestic mild cognitive impairment [13], there is sprouting and
expansion of presynaptic terminals, probably as a compensa-
tory mechanism, that is followed by a 15%–25% loss ofimer’s Association. This is an open access article under the CC BY-NC-ND
Fig. 1. Breakdown of publication selection. Schematic illustrating the sub-
selection of articles for meta-analysis. Abbreviation: AD, Alzheimer’s dis-
ease.
Fig. 2. Meta-analyses of synapse numbers in the hippocampus, frontal cortex, and
apse numbers in the different brain regions along with the forest plot of the standard
and temporal cortex; AD, Alzheimer’s disease; SD, standard deviation; CI, confid
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Specifically, a significant reduction in synapse numbers in
the CA1 region of the hippocampus and the inferior
temporal cortex has been demonstrated by electron
microscopy [16,17]. Moreover, recent studies found a
decrease in the dendritic proteins PSD-95 and drebrin in the
hippocampus and superior temporal cortex [18–20], whereas
synaptophysin was relatively preserved in these regions but
reduced in the dentate gyrus and frontal cortex [15]. In more
advanced forms of AD, there is a more severe loss of synapses
in the neocortex and limbic system varying from 20 to 40%,
depending on the methods to estimate synaptic alterations
[15,21–26] and reviewed by Scheff et al. [1].
Over the past 30 years, there have been over 400 publica-
tions focusing on analyzing synapses and synaptic marker
loss in postmortem tissues from patients with AD and con-
trol subjects. To provide a systematic overview of synapse
loss and the loss of synaptic markers in AD, 22 publications
provided data on synapse numbers and 83 publications
provided data on synaptic marker levels suitable for meta-
analyses. The advantage of using meta-analysis is that it
offers a way to compare a variety of parameters of synaptic
pathology with each other without requiring those parame-
ters to use the same scales or units of measurements. To
facilitate such comparisons, a database was built by calcu-
lating the standard mean difference (SMD) using theC,E,T. Information extracted from the articles for the meta-analysis of syn-
mean differences. Abbreviations: C,E,T, cingulate gyrus, entorhinal cortex,
ence interval; REML, restricted maximum likelihood.
Table 1
List of individual synaptic markers obtained from the included publications
Function Presynaptic Postsynaptic Presynaptic and postsynaptic
Adhesion Catenin beta
N-cadherin
NCAM
Calcium buffer Parvalbumin Calbindin
Calretinin
Calcium sensor Synaptotagmin
Calmodulin-binding protein Neurogranin
Cytoskeleton Septin 5 Drebrin Actin
Septin 7 Drebrin/actin
IRSp53
MAP2
SAPAP 1/GKAP
Synaptopodin
Endocytosis AP180
Dynamin 1
“Growth” or “plasticity” protein GAP43
Neuroendocrine secretory proteins Chromogranin A
Secretogranin 2
Neurotransmitter synthesis ChAT
Protein phosphatase Spinophilin Calcineurin
Ras GTPase-activating protein SynGAP SynGAP
Receptor G-0a TrkA
G-b
GBR1 GABAB receptor R1
G-ia
G-ia.1
G-protein a q/11
G-protein b common
G-sa
G-sa_s
Muscarinic M1
Muscarinic M4
NR1
NR2A
NR2B
Redox proteins Thioredoxin
Signaling CaMKIIa
CaMKIIb
pCaMKII
PSD95
TotalCaMKII
Small GTPase Rab3a
Rab5
Rab7
SNARE Complexin 1
Complexin 2
SNAP25
Synaptobrevin
Synaptobrevin 2
Syntaxin
Syntaxin 1
Syntaxin 1A
Syntaxin 1B
VAMP2
VAMP2/3
Tethering Synapsin-1
Transporter ZnT1
Vesicular SV2
Synaptophysin
VGLUT1
VGLUT2
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Table 2
Detailed summary of the standard mean differences of the meta-analysis for presynaptic and postsynaptic markers by brain region
Marker Hippocampus Frontal cortex C,E,T Cingulate gyrus Entorhinal cortex Temporal cortex Amygdala
Presynaptic
Vesicle-related proteins [2,20,21,
47–87,124,125]
21.56 21.49 22.06 20.59 23.45 21.51
Cell adhesion [78,88,89] 0.14 22.79 21.62 21.62
Calcium buffer [90–97] 23.74 25.11 21.84 21.84
Calcium sensor [20,55,63,72,77,98] 21.07 20.46 21.45 21.19 21.7
Cytoskeleton [21,89,99] 1.89 20.95 20.33 20.33
Endocytosis [52,78] 21.2 20.44 21.39 22.2 20.74
Neuroendocrine secretory proteins [63,80] 20.28 0.22 0.22
Neurotransmitter synthesis [97]
Protein phosphatase [100]
Receptor [101,102] 21.59 21.53 21.63 21.42
Redox proteins [103] 21.23 20.85 21.16
Small GTPase [55,72,77,104–106] 0.01 0.18 21.28 21.28
SNARE [19,21,67,72,77,78,85,107,108] 20.15 21.31 21.18 20.79 21.56
Tethering [19,77,109–112] 20.87 20.79 0.15 0.49 20.14 0.11
Overall presynaptic markers 21.21 21.35 21.62 20.58 22.47 21.34 21.16
Postsynaptic
Cell adhesion [78,88,89] 0.14 22.79 21.62 21.62
Calcium buffer [91,93–97] 25.11 22.21 22.21
Calmodulin-binding protein [55,72] 20.62 20.36
Cytoskeleton [20,54,64,65,72,89,99] 21.02 20.86 21.74 21.99 21.34 21.77
Growth factor related [55,72,113–115] 21.05 20.42
Protein phosphatase [64,65,100,116] 21.66 21.08 20.44 20.44
Ras GTPase-activating protein
SynGAP [89]
Receptor [101,102,117–121] 20.2 0.18 21.88 21.63 22.83 21.51
Redox proteins [103] 21.23 20.85 21.16
Signaling [19,64,65,67,86,89,122] 0.13 0.61 0.22 2.74 20.72
Transporter [123] 4.04 23.29 3.23
Overall postsynaptic markers 20.33 21.06 21.54 20.8 21.25 21.76 1.04
Overall synaptic markers 21.04 21.12 21.56 20.55 22.2 21.4 3.23
Abbreviation: C,E,T, cingulate gyrus, entorhinal cortex, and temporal cortex.
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parameter in each study. The present meta-analysis study
showed a consistent synaptic loss across brain regions and
that the molecular machinery involved in endosomal path-
ways, vesicular assembly mechanisms, glutamate receptors,
and axonal transport are often affected.2. Methods
2.1. Search strategy and selection criteria
Literature published from 1980 to February, 15th 2015
was systematically screened in the Cochrane Central Regis-
ter of Controlled Trials, MEDLINE, and Embase electronic
databases according to PRISMA guidelines [27] using the
following search terms in the title, abstract, or descriptors:
½ðAlzheimer  OR dement  ÞANDðsynap  OR spine 
OR boutonÞ
The search resulted in 15,217 results that were imported
into EndNote. Duplicate references (6268) were automati-cally removed, followed by manual examination, which
retrieved another 658 duplicate references (Fig. 1). Confer-
ence abstracts (1628) and non-English publications (272)
were also excluded from the database (Fig. 1). The title
and abstract of the remaining 6391 publications were evalu-
ated according to predefined inclusion (AD population; syn-
aptic marker levels, synapse and/or dendritic spine counts)
exclusion (non-AD population, non-human data, review/
opinion articles) criteria.
We retrieved 417 publications reporting synapse counts
or levels of synaptic proteins in patients with AD and cogni-
tively intact elderly, even if not explicitly mentioned in the
abstract. The full-text of these publications were analyzed
according to the following inclusion criteria: contained
AD patient population according to the National Institute
of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association
criteria [28] and/or the Diagnostic and Statistical Manual
for Mental Disorders [29] criteria for AD and mentioned
the use of a cognitively intact elderly control group, mean
and standard deviation or standard error for synapse counts
and/or synaptic proteins levels, number of AD patients and
Basal
forebrain Basal ganglia Cerebellum Cortex Insular Mesencephalon Motor cortex Neocortex
Occipital
cortex Parietal cortex Thalamus
20.03 0.85 25.58 20.4 22.65 20.87 22.06 0.28
24.15 0.54
20.43
20.12 20.26 0.08
20.64 0.59
20.33
27.27
0.5 20.24
28.62 20.48 21.93
1.27 0.15 20.01 0.09 21.22
20.48 20.71 20.54 20.88
0.51 20.04 0.21
21.46 0.02 0.12 23.32 20.71 20.04 20.4 22.65 20.55 21.57 0.28
24.15 0.54
20.43
20.37
20.9 22.42 22.44 0.03
0.43 20.27
0.5 20.24
20.35
28.62 21.15 20.84 20.83
21.21 21.55 21.08
3.05
23.16 21.15 20.22 22.14 21.55 20.79 20.36
21.46 20.13 20.05 22.21 20.71 20.04 20.04 22.38 20.65 21.21 0.28
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groups. The following publications were excluded: those
reporting on gene expression, messenger RNA expression,
and receptor binding studies (Fig. 1).2.2. Data collection
Of 417 publications, 103 publications met all inclusion
criteria (Fig. 1); 20 publications reported counts of synapses
[3,17,23,30–46], 81 publications reported synaptic
protein levels [2,19–21,47–123], and two publications
reported both [124,125]. Collectively, the 83 publications
[2,19–21,47–125] reported 67 different synapse-related pro-
teins in 17 different brain areas. Because not every possible
combination of a synapse protein and brain area has been
studied or reported usable data to allow inclusion to the
meta-analyses, approximately 35% of these possible
combinations were available and provided data suitable for
meta-analyses.
Data from the identified publications were extracted on
synapse counts and/or synapse protein levels, number of
subjects, and average age of the AD and control groups.SMDs were calculated based on the difference between the
control and the AD groups took into account the variation
within the groups and the number of subjects per group.
For publications where more than onemeasurement was per-
formed, this resulted in more than one SMD, e.g., when
synaptophysin was measured in hippocampus, temporal
cortex, and entorhinal cortex, three different SMDs were
calculated.2.3. Statistical analysis
All reported comparisons of synapse counts and synapse
protein levels in AD patients and controls were integrated
and summarized into a final result per brain area-synaptic
protein combination, using meta-analysis (regression)
methods [126], according to the PRISMA statement [27].
For meta-analysis, a minimum of four publications was
required [127,128]. Comparison across studies did not
require conversion to the same unit because our analysis
was based on the difference between groups, i.e., not on
the absolute value. These data were analyzed using the
random-effects meta-analysis model [126] fitted by
Table 3
Further summarization of the standard mean differences for presynaptic and postsynaptic markers in different brain areas
Marker Hippocampus Frontal cortex C,E,T
Presynaptic
Calcium regulation [90,92–96] 23.74 25.11 21.84
Cytoskeleton [21,99] 1.89 20.95 20.33
Vesicular organization [2,19–21,47–81,98,104,105,108–112,124,125] 21.03 21.15 21.61
Grand total presynaptic 21.21 21.35 21.62
Cell adhesion [78,88] 0.14 22.79 21.62
Postsynaptic
Calcium regulation [55,72,93–96,122] 20.62 22.39 21.67
Cytoskeleton [20,54,64,65,72,99,116] 21.45 20.92 21.55
Intracellular signaling [19,55,64,65,67,72,113,115] 21.05 20.08 1.01
Neurotransmission [117–121] 20.2 0.63 21.96
Grand total postsynaptic 20.33 21.06 21.54
Overall effect 21.04 21.12 21.56
Abbreviation: C,E,T, cingulate gyrus, entorhinal cortex, and temporal cortex.
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from Stata (Statistical Software: Release 12.1; StataCorp
2001, College Station, TX, USA). As synapse numbers
and synaptic proteins were also affected by aging, meta-
analyses were conducted with and without a correction by
meta-regression for differences in mean age between AD
patients and controls.
2.4. Analysis of bias
According to the PRISMA statement [27], the quality of a
systematic review depends on the quality of the individual
publications and the absence of bias for their inclusion.
The quality of the studies was assessed by several inclusion
and exclusion criteria (listed in section 2.1, Search strategy
and selection criteria). Furthermore, results of the meta-
analyses were statistically analyzed for possible bias
because meta-analyses that are based on small studies
reporting larger (smaller) effects may tend to overestimate
(underestimate) the actual outcome. Funnel plots, which
plot the standard error against the reported mean difference
for each publication, can indicate the overestimation or
underestimation of the actual difference occurring in the
meta-analysis. Therefore, we used Egger’s test as imple-
mented in the Stata program meta-bias [129] to test the
association between standard error and effect size in the
funnel plot. For this analysis, a minimum of eight publica-
tions is generally recognized to be required [127,128].3. Results
Of 103 references that met all inclusion criterion, 22 ref-
erences were used to evaluate the extent to which changes in
synapse numbers occurred in different brain regions that are
affected in AD. A meta-analysis of the number of synapses
was performed in the hippocampus, frontal cortex, and in
the combined regions of the cingulate gyrus, entorhinal cor-
text, and temporal cortex (C,E,T). Data analysis of patients
with AD revealed consistently lower synapse numbers in
the hippocampus, the frontal cortex, and in the C,E,T(Fig. 2) compared with those in the control group. Synapse
numbers were most affected in the hippocampus (SMD
22.12) followed by the C,E,T (SMD22.55) and the frontal
cortex (SMD 21.31 Fig. 2), using the SMD method.
Because synapse numbers were reduced in the hippocam-
pus, C,E,T, and frontal cortex, we performed a second
meta-analysis of the effect of AD on 67 presynaptic
and postsynaptic markers to determine if specific molecular
pathways in the synapse were selectively affected
in AD (Table 1). The most widely analyzed synaptic
marker in the brains of AD patients is the synaptic
vesicle protein synaptophysin [1,12]; however, several
other synaptic proteins have been shown to be
altered in the brains of patients with AD including
synaptobrevin [19,72,77], SNAP25 [19,21,77,108],
synaptotagmin [20,55,63,72,77,98], syntaxin [19,21,67,77],
Rab3a [55,72,77,104], synapsin I [19,77,109–112], and the
postsynaptic proteins PSD-95 [19,64,65,67], Homer, and
IRSp53 [89]. The 83 publications reported at least one synaptic
marker level and combined provided information on 67
different markers (Table 1). Combining results together in one
comparison shows on which markers and brain areas
research has focused and which markers and brain areas
are underrepresented in the overview (Table 2). Using the
SMD allowed us to pool 67 different synaptic markers into
a single overall database for comparison [19–21,52,55,
63–65,67,72,77,78,80,85,86,88–123]. Irrespective of the brain
area, these synaptic markers can be divided into 28
presynaptic markers in 10 functional categories, 30
postsynaptic markers in eight functional categories, and nine
markers in six functional categories without specific
presynaptic or postsynaptic localization (Table 2).
After the combination of the 67 synaptic markers from
all brain regions into one database, we used the same
regional division of the brain into hippocampus, frontal
cortex, and C,E,T. As a result, we evaluated 57 different
synaptic markers retrieved from a selection of 70 publica-
tions which reported results for the brain regions of interest:
hippocampus, frontal cortex, and C,E,T (Table 3). These
Fig. 3. Presynaptic and postsynaptic marker changes in different brain areas. Schematic representation of the standard mean differences (SMD) for presynaptic
and postsynaptic markers in the hippocampus, the frontal cortex, C,E,T (cingulate gyrus, entorhinal cortex, and temporal cortex), and the remaining. Presynaptic
markers are more affected by AD than the postsynaptic markers in all areas observed. These differences vary by brain area with the hippocampus showing the
greatest difference and the C,E,T showing the smallest difference. SMD’s are listed in each summarizing structure, for the overall presynaptic and postsynaptic
change and for the overall change per brain area. Green-to-red color change depicts an increase or decrease of synaptic markers in comparison with healthy
controls, where more green indicates stronger increase and more red stronger decrease. Abbreviations: C,E,T, cingulate gyrus, entorhinal cortex, and temporal
cortex; AD, Alzheimer’s disease.
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functional categories, 25 postsynaptic markers in
seven functional categories, and seven markers in five
functional categories without specific presynaptic or
postsynaptic localization (Table 3). Irrespective of the
synaptic markers, the hippocampus and the frontal
cortex showed equal reduction of synaptic markers with
SMDs of 21.04 and 21.12, respectively (Table 3). The
C,E,T were affected slightly more with a SMD of 21.56.
In the three evaluated brain areas, presynaptic markers
were affected more than postsynaptic markers; however,
this difference was stronger in the hippocampus (pre-
SMD 21.21 vs. post-SMD 20.33) than in the frontal
cortex (pre-SMD 21.35 vs. post-SMD 21.06) and the
C,E,T (pre-SMD 21.62 vs. post-SMD 21.54).
Summarizing the data further showed that some aspects of
synaptic organization were affected to a similar extent across
brain regions, whereas other aspects of synapse function wereaffected differently (Fig. 3). More specifically, calcium
homeostasis was negatively affected both presynaptically
and postsynaptically in all the brain regions. Vesicular organi-
zation was decreased in the hippocampus (SMD 21.03) and
frontal cortex (SMD21.15) and strongest in the C,E,T (SMD
21.61). Intracellular signaling was hardly affected in the
frontal cortex (SMD 20.08), whereas it was negatively
affected in the hippocampus (SMD 21.05) and C,E,T
(SMD 21.96; Fig. 3 and Table 3). Similarly, postsynaptic
cytoskeleton organization was decreased in all brain areas
(hippocampus 21.45, frontal cortex 20.92, and C,E,T
21.55), whereas presynaptic cytoskeleton organization
showed a reduced SMDof20.95 in the frontal cortex andmi-
nor changes in the C,E,T (SMD of 20.33), although in the
hippocampus, there was an increased SMD of 1.89 (Fig. 3).
Another difference between the hippocampus and the other
two brain regions, the frontal cortex, and the C,E,T, was the
lack of changes in cell adhesion markers (SMD 0.14) in the
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cortex (SMD 22.79) and the C,E,T (SMD 21.62; Fig. 3).4. Discussion
The present study reviewed 417 references on synaptic
pathology in AD and performed meta-analysis for synapse
number (22 publications) and synaptic proteins in a subset
of these references (83 publications). The benefits of using
meta-analysis are clearly illustrated by the potential of a
single database to bring together publications on synaptic
pathology, which can growwhen data from new publications
and existing data (from publications not presenting means
plus standard deviations) are added. An additional benefit
of this approach is that it allows comparison of the collective
results of 83 publications with proteomics studies. The cur-
rent results are consistent with recent proteomics studies in
synaptosomal preparations indicating that proteins such as
Rabs, synaptotagmin, annexins, heat shock proteins, gluta-
thione, and others that are involved in regulating energy
and calcium metabolism and are dysregulated in AD, such
as signal transduction, vesicle transport, and antioxidant
activity [89,130,131].
Interestingly, more recent proteomics studies with post-
synaptic density preparations from AD patients have shown
that brain-specific angiogenesis inhibitor 1–associated pro-
tein 2 (IRSp53) was altered. IRSp53 belongs to a family of
proteins harboring IRSp53–MIM domain that is associated
with both actin and lipids [89]. This cluster of proteins regu-
lates the spine cytoskeleton and membrane trafficking.
IRSp53 interacts with postsynaptic density scaffold proteins
(e.g., PSD-95 and chapsyn-110/PSD-95 and Rabs to modu-
late dendritic structure [89]). Thus, alterations observed in
the brains of patients with AD might reflect defects in den-
dritic spine motility and disorganization of the postsynaptic
scaffolds [19].
Although the earliest and most significant alterations in
postmortem studies in AD and in APP tg models appear to
be in proteins located in the presynaptic site, it is likely
that both the presynaptic and postsynaptic compartments
are affected because the soluble synaptotoxic hydrophobic
Ab oligomers diffuse rapidly between the axonal and den-
dritic partition [12,132]. Together, these studies suggest
that at early stages of AD, soluble Ab oligomers that
diffuse from cell to cell might exert their toxic effects by
locally affecting in the presynaptic site the SNARE
machinery components, Rabs, calcium sensors, and anti-
oxidant molecules and in the postsynaptic site glutamate
receptors, postsynaptic density scaffold molecules, and
mitochondria. Moreover, these oligomers might engage syn-
aptic receptors that trigger neurotoxic signaling pathways
(e.g., Fyn, CDK5, GSK3b) that merge in tau dependent
and independent pathways [133–135].
A challenge of the current methodology is that most
studies included in the meta-analysis approach consist of
rather small studies. The average study population size is10 subjects in the AD group versus 10 subjects in the healthy
elderly control group. These small sample sizes carry the
risk of publication bias, which is observed in the synapse
count meta-analyses for hippocampus and frontal cortex.
To overcome this problem, future research should aim for
larger study populations, which will improve the intrinsic
power of the individual study and also the overall power of
meta-analysis approaches.
In conclusion, the present meta-analysis study showed a
consistent synaptic loss across brain regions and that the mo-
lecular machinery involved endosomal pathways, vesicular
assembly mechanisms, glutamate receptors, and axonal
transport are often affected. Based on these findings, future
research focusing on a set of crucial experiments that are de-
signed to methodically test the hypothesis that synapse loss
is due to soluble Ab oligomers exerting their toxic effects by
locally affecting the molecular machinery in the presynaptic
site including the SNARE machinery components, Rabs,
calcium sensors, and anti-oxidant molecules and in the
post-synaptic site glutamate receptors, postsynaptic density
scaffold molecules and mitochondria would greatly advance
our scientific understanding of synapse loss in AD.
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1. Systematic review: The authors reviewed the litera-
ture on the molecular underpinnings and progression
of synapse loss in Alzheimer’s disease and found that
although several studies have been published, but to
date no meta-analysis that is inclusive of all the
publications has been considered.
2. Interpretation: Our findings from the meta-analysis
of close to 100 of the most important publications
showed a consistent synaptic loss across brain re-
gions and that the molecular machinery including
endosomal pathways, vesicular assembly mecha-
nisms, glutamate receptors, and axonal transport are
often affected.
3. Future directions: The article synthesized data from
over 100 articles on synaptic markers and synapse
loss; however, owing to the small average sample
sizes for both the control and Alzheimer’s disease
groups (n5 10), future research should aim for larger
study populations, which will improve the intrinsic
power of the individual study and also the overall po-
wer of meta-analysis approaches.
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